Companies aren’t waiting for New York’s health departments to finalize key details of its medical-marijuana program to start selling cannabis-based products.

Axim Biotech, which has offices in New York and the Netherlands, wants to sell a line of anti-inflammatory, cannabis-based toothpaste and mouthwash that the company claims could be on drugstore shelves by this fall, along with a line of skin-care products.

Its dental products won’t require any FDA regulation because they are not considered medical, said Chief Executive Dr. George Anastassov. Sold under the brand name Oraximax, they will be “priced competitively,” said the company’s chief medical officer, Dr. Philip Van Damme.

Axim is also developing cannabinoid-based pharmaceuticals in its Netherlands location. It currently is conducting a clinical trial for a cannabinoid-based painkiller that is expected to come on the market in two years, Dr. Anastassov said. “There has been nothing new in the pain-management market for the last 30 years,” he said. “Meanwhile, the population is aging, and people have a much more active lifestyle than they used to.” [Read more at Crain’s New York Business]